{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:11:27Z","timestamp":1773335487071,"version":"3.50.1"},"reference-count":31,"publisher":"Jaypee Brothers Medical Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.59556\/japi.74.1324","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:39:33Z","timestamp":1773293973000},"page":"20-22","source":"Crossref","is-referenced-by-count":0,"title":["Dabigatran-induced Gastrointestinal Bleed Treated by 4-factor Prothrombin Complex Concentrate in a Tertiary Care Hospital in Sikkim"],"prefix":"10.59556","volume":"74","author":[{"given":"Mona","family":"Dhakal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Om Prakash","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilay","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartikeya","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"key":"key20260312053924_B1","volume-title":"Pradaxa\u00ae","year":"2014."},{"key":"key20260312053924_B2","doi-asserted-by":"crossref","first-page":"1139\u2013","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361:","author":"Connolly","year":"2009;","journal-title":"N Engl J Med"},{"key":"key20260312053924_B3","doi-asserted-by":"crossref","first-page":"727403.","DOI":"10.3389\/fneur.2021.727403","article-title":"Dabigatran reversal with idarucizumab and in-hospital mortality in intracranial hemorrhage: a systematic review of real-life data from case reports and case series.","volume":"12:","author":"Frol","year":"2021;","journal-title":"Front Neurol"},{"key":"key20260312053924_B4","doi-asserted-by":"crossref","first-page":"e144.","DOI":"10.3324\/haematol.2013.092767","article-title":"Use of prothrombin complex concentrates for urgent reversal of dabigatran in the emergency department.","volume":"98:","author":"D\u00edaz","year":"2013;","journal-title":"Haematologica"},{"key":"key20260312053924_B5","doi-asserted-by":"crossref","first-page":"1429\u2013","DOI":"10.1097\/ALN.0000000000000255","article-title":"Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.","volume":"120:","author":"van Ryn","year":"2014;","journal-title":"Anesthesiology"},{"key":"key20260312053924_B6","doi-asserted-by":"crossref","first-page":"259\u2013","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate.","volume":"49:","author":"Stangier","year":"2010;","journal-title":"Clin Pharmacokinet"},{"key":"key20260312053924_B7","doi-asserted-by":"crossref","first-page":"386\u2013","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.","volume":"36:","author":"Blech","year":"2008;","journal-title":"Drug Metab Dispos"},{"key":"key20260312053924_B8","doi-asserted-by":"crossref","first-page":"131395.","DOI":"10.1155\/2013\/131395","article-title":"Coagulopathy and extremely elevated PT\/INR after dabigatran etexilate use in a patient with end-stage renal disease.","volume":"2013:","author":"Kim","year":"2013;","journal-title":"Case Rep Med"},{"key":"key20260312053924_B9","doi-asserted-by":"crossref","first-page":"1066\u2013","DOI":"10.1016\/j.amjcard.2013.11.049","article-title":"Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.","volume":"113:","author":"Bloom","year":"2014;","journal-title":"Am J Card"},{"key":"key20260312053924_B10","doi-asserted-by":"crossref","first-page":"S141\u2013","DOI":"10.1002\/ajh.23202","article-title":"Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.","volume":"87:","author":"Kaatz","year":"2012;","journal-title":"Am J Hematol"},{"key":"key20260312053924_B11","doi-asserted-by":"crossref","first-page":"1533\u2013","DOI":"10.2215\/CJN.01570213","article-title":"Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.","volume":"8:","author":"Singh","year":"2013;","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20260312053924_B12","doi-asserted-by":"crossref","first-page":"487\u2013","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis.","volume":"61:","author":"Chang","year":"2013;","journal-title":"Am J Kidney Dis"},{"key":"key20260312053924_B13","volume-title":"Multaq\u00ae","year":"2014."},{"issue":"(4):","key":"key20260312053924_B14","doi-asserted-by":"crossref","first-page":"728\u2013","DOI":"10.1160\/TH14-08-0712","article-title":"Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab.","volume":"113","author":"Honickel","year":"2015;","journal-title":"Thromb Haemost"},{"key":"key20260312053924_B15","doi-asserted-by":"crossref","first-page":"R27.","DOI":"10.1186\/cc13717","article-title":"Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation\/liver trauma experimental model.","volume":"18:","author":"Grottke","year":"2014;","journal-title":"Crit Care"},{"key":"key20260312053924_B16","first-page":"113(5):943\u2013951.","article-title":"A randomized study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.","author":"Glund","year":"2015;","journal-title":"Thromb Haemost"},{"key":"key20260312053924_B17","doi-asserted-by":"crossref","first-page":"115.","DOI":"10.1186\/s13054-016-1275-8","article-title":"Efficacy of prothrombin complex concentrates for the emergency reversal of transmigrate-induced anticoagulation.","volume":"20:","author":"Grottke","year":"2016;","journal-title":"Crit Care"},{"key":"key20260312053924_B18","doi-asserted-by":"crossref","first-page":"308\u2013","DOI":"10.1111\/bjh.12620","article-title":"Activated prothrombin complex concentrate for dabigatran-associated bleeding.","volume":"164:","author":"Schulman","year":"2014;","journal-title":"Br J Haematol"},{"key":"key20260312053924_B19","doi-asserted-by":"crossref","first-page":"169\u2013","DOI":"10.4037\/ajcc2013125","article-title":"Dabigatran etexilate: management in acute ischemic stroke.","volume":"22:","author":"Javedani","year":"2013;","journal-title":"Am J Crit Care"},{"key":"key20260312053924_B20","doi-asserted-by":"crossref","first-page":"1646\u2013","DOI":"10.2146\/ajhp120055","article-title":"Reversal of transmigrate-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.","volume":"69:","author":"Dumkow","year":"2012;","journal-title":"Am J Health Syst Pharm"},{"key":"key20260312053924_B21","doi-asserted-by":"crossref","first-page":"2428\u2013","DOI":"10.1161\/CIRCULATIONAHA.112.123224","article-title":"Periprocedural management and approach to bleeding in patients taking dabigatran.","volume":"126:","author":"Weitz","year":"2012;","journal-title":"Circulation"},{"key":"key20260312053924_B22","doi-asserted-by":"crossref","first-page":"427\u2013","DOI":"10.1007\/s11239-014-1112-3","article-title":"Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report.","volume":"39:","author":"Masotti","year":"2015;","journal-title":"J Thromb Thrombolysis"},{"key":"key20260312053924_B23","doi-asserted-by":"crossref","first-page":"583\u2013","DOI":"10.1160\/TH12-03-0149","article-title":"Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.","volume":"108:","author":"Lillo-Le Louet","year":"2012;","journal-title":"Thromb Haemost"},{"key":"key20260312053924_B24","first-page":"148.","article-title":"Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Abstract presented at: 13th Congress of the European Hematology Association.","volume":"93:","author":"van Ryn","year":"2008;","journal-title":"Haematologica"},{"key":"key20260312053924_B25","doi-asserted-by":"crossref","first-page":"1841\u2013","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model.","volume":"10:","author":"Pragst","year":"2012;","journal-title":"J Thromb Haemost"},{"key":"key20260312053924_B26","doi-asserted-by":"crossref","first-page":"353\u2013","DOI":"10.1097\/ALN.0000000000000540","article-title":"Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.","volume":"122:","author":"Hoffman","year":"2015;","journal-title":"Anesthesiology"},{"key":"key20260312053924_B27","doi-asserted-by":"crossref","first-page":"1830\u2013","DOI":"10.1111\/j.1538-7836.2012.04863.x","article-title":"Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.","volume":"10:","author":"Lambourne","year":"2012;","journal-title":"J Thromb Haemost"},{"key":"key20260312053924_B28","doi-asserted-by":"crossref","first-page":"1573\u2013","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate.","volume":"124:","author":"Eerenberg","year":"2011;","journal-title":"Circulation"},{"key":"key20260312053924_B29","doi-asserted-by":"crossref","first-page":"1914\u2013","DOI":"10.2146\/ajhp130243","article-title":"Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations.","volume":"70:","author":"Nutescu","year":"2013;","journal-title":"Am J Health Syst Pharm"},{"key":"key20260312053924_B30","doi-asserted-by":"crossref","first-page":"155\u2013","DOI":"10.1177\/1756285614528064","article-title":"Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry.","volume":"7:","author":"Tsivgoulis","year":"2014;","journal-title":"Ther Adv Neurol Disord"},{"issue":"(3):","key":"key20260312053924_B31","doi-asserted-by":"crossref","first-page":"332\u2013","DOI":"10.1007\/s12664-022-01324-6","article-title":"Position statement from the Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India on gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and\/or anticoagulant therapy.","volume":"42","author":"Arora","year":"2023;","journal-title":"Indian J Gastroenterol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:39:37Z","timestamp":1773293977000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-3-s1-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.59556\/japi.74.1324"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1324","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}